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ABSTRACT
In this study, a series of taurinamide derivatives were synthesized 
and screened for their antimicrobial activity. The structures of 
the newly synthesized compounds 11-15 were evaluated by 
1H NMR, IR, MS-APCI and elemental analysis. Compounds 
(1-15) were tested against standard strains of Gram(+), 
Gram(−) bacteria and fungi by using disc diffusion and broth 
microdilution methods. Although disc diffusion method did 
not show any comparable results due to the solubility properties 
of the compounds; microdilution method results indicated that 
title compounds showed from poor to good activity against 
only Enterococcus faecalis. It can be concluded that phtalimido 
moiety, secondary aryl sulphonamide group and electron-
donating group substitution on phenyl ring are essential for 
the antibacterial activity. Among the tested compounds, para 
substituted methyl and methoxy derivatives of N-phenyl-2-
phthalimidotaurinamide (4, 7), displayed equipotent activity 
compared to standard drug gentamicin.
Key Words: Taurinamide, N-substituted-2-
phtalimidoethanesulfonamide, antibacterial, Enterococcus 
faecalis, microdilution.
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Introduction
Infectious diseases are a challenging area for drug development 
studies as bacteria have variable resistant mechanisms to 
existing antimicrobials. It had been reported as the major 
public health problem by World Health Organization 
(WHO) in 2014 (1). In fact, there is a lack in development of 
new drugs and mortality rates are increasing due to bacterial 
infections. As a consequence, antibacterial drug development 
studies become an urgent area in medicinal chemistry (2, 
3). The strategies for developing new compounds, mostly 
based on synthetic modifications of natural antibiotics and 
synthetic antibacterials like sulfonamides (4). Among these 
methods, molecular hybridization is known to be one of 
the most useful one for manipulating the pharmaceutical, 
pharmacokinetic or pharmacodynamic properties of the 
parent compound (5).
Phtalimide moiety (I) is a versatile structure that enable 
different variation of substitutions while amino acid 
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substituted derivatives from nitrogen known to possess strong 
antibacterial activity (6). Although the clear interaction 
mechanism is not known, it is considered to interact with 
host’s mRNA (7). On the other hand, it is known for its 
anticonvulsant (8), antitubercular (9), antitumor (10) and 
anti-inflammatory effects (11).
Taurinamide (II) is lipophilic derivative of taurine and 
known to posses antibacterial (12), histamine H4 receptor 
inverse agonists (13) and anticonvulsant (14) activities which 
indicate its potential for generating pharmacologically active 
compounds.
Sulfonamide scaffold is a building-block which creates 
antidiabetic (15), carbonic anhydrase inhibitor (16), anti-
inflammatory (17) and antitumor (18) drug molecules. 
Moreover, the most prominent effect is antibacterial activity 
as various sulfonamide (III) derivatives are in clinical use for 
decades (19).
In the literature, introduction of electron withdrawing (i.e. 
chloro) and donating (i.e. methoxy, methyl) groups on 
different positions of the phenyl moiety considered to have 
diverse effects on biological activities (20). On the other 
hand, morpholine is the mostly used scaffold in drug design 
studies (21) and plays an important role in exerting antifungal 
activity by inhibiting the biotransformation of sterols (22).
According to above considerations, we designed and 
synthesized a group of taurinamide (II) derivative for evaluating 
their antimicrobial activity. The title compounds 1-13 have 
phtalimide scaffold tailored with taurine and functionalized 
as sulfonamide from its sulfonic acid part with ammonium 
hydroxide, morpholine and nonsubstituted/substituted aniline 
derivatives. On the other hand, deprotection of phtalimido 
moiety from nonsubstituted aniline and morpholine 
derivatives furnished compounds 14 and 15.
The title compounds 1-10 were reported in our previous 
study whereas 11-15 were reported in different studies as 
intermediates of diverse compounds (12, 13, 23). None of 
the compounds have been tested for their antimicrobial 
activity before though taurine derivatives known to posses 
antimicrobial activity (12, 24). Literature survey indicates 
that there is a need for elucidating the structural requirements 
that mediates their phamacological activity (25). This study 
will provide us to compare the alteration on antimicrobial 
activity due to aliphatic, aromatic and phtalimide substitution 
on taurinamide structure.
Results and Discussion
1.Chemistry
The target molecules 1-10 were synthesized as outlined in 
Figure 1. Taurine and phtalic anhydride were condensed to 
give 2-phthalimidoethanesulfonic acid potassium salt A and 
this compound was converted to its chlorinated derivative 
B with phosphorus pentachloride. Compound B was then 
reacted with corresponding aniline derivatives to yield the 
title compounds 1-10. The detailed synthetic procedure and 
their characterizations by 1H NMR, IR, mass spectral data and 
elemental analysis were reported in our previous study (23).
Title compounds 11-15 were synthesized starting from 
2-phtalimidoethanesulfonyl chloride B which was prepared 
according to procedure described before (12, 13). The 
chlorinated derivative B was reacted with sulfanilamide in 
pyridine to give the title compound 11 as a white solid (Figure 
2). 1H NMR spectrum of the compound 11 displayed two 
singlets at 10.50 ppm and 7.31 ppm indicating the existence 
of secondary and primary sulfonamide groups respectively. 
Three N-H stretching bands between 3361 and 3245 cm-
1, two SO2 asymmetric (1304, 1319 cm-1) and SO2 symetric 
stretching bands (1141, 1160 cm-1), were confirmative for the 
title compound’s structure in IR spectrum.
Reaction of B with ammonium hydroxide solution furnished 
the title compound 12 (Figure 2). The structural confirmation 
was provided by the existence of broad singlet shown at 
7.06 ppm in 1H NMR spectra. It was indicative for primary 
sulfonamide protons as their chemical shift were observed at 
the upfield compared to the aromatic sulfonamide protons 
in compound 11. On the other hand; two NH stretching, 
one SO2 asymmetric and SO2 symmetric stretching bands 
confirmed the title compound’s structure in IR spectrum.
The title compound 13 was obtained by the reaction of 
B with morpholine and TEA in DCM solution at room 
temperature (Figure 2). Disappearance of SO2NH proton 
signal from aromatic field, appearance of the 2 triplets at 3.66 
and 3.19 ppm in 1H NMR spectrum and absence of the NH 
strecthing bands in IR spectrum supported the substition of 
morpholine for compound 13.
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Deprotection of the compounds 1 and 13 were performed 
according to Ing-Manske procedure (26) (Figure 1-2). The 
absence of the carbonyl stretching bands at 1700 cm-1 region, 
existence of the broad NH stretching bands at 2600, 2800 
cm-1 in IR spectra and disappearance of phtalimide protons 
from aromatic region in 1H NMR spectra were confirmative 
findings for the structures of the title compounds 14-15.
Mass spectra of compounds 11, 12 and 13 displayed two 
main fragmentation patterns as m/z 238 ion [C10H8NO4S]+ 
and m/z 174 ion [C10H8NO2]+ which were in agreement 
with the previously reported derivatives 1-10. On the other 
hand [M+1]+ ion peaks were observed for the deprotected 
derivatives 14-15.
The compounds 11-15 were reported earlier though were not 
fully characterized by spectral data.
2. Antimicrobial Activity
All the title compounds were screened for antibacterial 
activity against Staphylococcus aureus ATCC 29213, 
Enterococcus faecalis ATCC 29212 (Gram positive); 
Escherichia coli ATCC 25922 and Pseudomonas Aeruginosa 
Figure 1. Synthesis of title compounds 1-10, 14.
Figure 2. Synthesis of title compounds 11-15.
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ATCC 27853 (Gram negative) bacterial strains in addition 
to their antifungal activities against Candida Albicans ATCC 
90028 and Candida parapsilosis ATCC 22019. Disc diffusion 
and broth microdilution methods were used to evaluate the 
antimicrobial activity in a qualitative and quantitative way 
respectively.
Preliminary screening tests was performed by using 
disc diffusion method for detecting the susceptibility of 
microorganisms to the title compounds (Table 1). The results 
showed that Staphylococcus aureus (S. aureus) is susceptible 
only to compound 9, while Enterococcus faecalis (E. faecalis) 
is susceptible to the title compounds 9, 11, 12 with about 8 
mm inhibition zone which is not closely relative to standard 
drugs gentamicin and co-trimoxazole. Since the literature 
survey indicates that the solubility of the compounds is 
a limiting factor on the diffusion rate through the agar 
medium, we decided to employ broth microdilution method 
for overcoming this problem (27). Disc diffusion and broth 
microdilution methods did not show any comparable results 
which can be explained by the poor solubility and polar 
character of the title compounds (28).
Broth microdilution method results showed that none of the 
title compounds displayed significant antimicrobial activity 
against tested microorganisms except E. faecalis (Table 2). 
The cause of poor activity can be explained by wide range 
of resistant mechanism of S. aureus and different cell wall 
structures of Gram-negative bacteria and fungi (22,29). 
For this reason, the following structure activity relationship 
(SAR) will be discussed only for E. faecalis (Table 2):
1. Phtalimidotaurinamide [2-(1,3-dioxoisoindolin-2-yl)
ethanesulfonamide] 12 and its N-phenyl substituted 
derivative 1 exhibited equal activity by 256 µg/ml (MIC 
value) whereas removal of the phtalimide moiety from 
1 yielded in a 4 fold decreased activity by 1024 µg/ml as 
MIC value.
2. Compound 13, which has morpholine substituted tertiary 
sulfonamide group, yielded in a poor antibacterial activity 
with 1024 µg/ml (MIC value) compared to all other 
substituted phtalimidotaurinamide derivatives 1-12. 
Moreover the antibacterial activity diminished with its 
deprotected derivative 15.
Table 1. In vitro anti-bacterial and anti-fungal activities of compounds 1-15 by disc diffusion methoda
Comp. No
Bacterial strains Fungal strains
Gram( +) Gram( −) C. albicans C.parapsilosis
S. aureus E. faecalis E. coli P. aeruginosa
1 - - - - - -
2 - - - - - -
3 - - - - - -
4 - - - - - -
5 - - - - - -
6 - - - - - -
7 - - - - - -
8 - - - - - -
9 8±0 7.33±0.58 - - -
10 - - - - - -
11 - 8±1 - - - -
12 - 8±1 - - - -
13 - - - - - -
14 - - - - - -
15 - - - - - -
DMSO - - - - - -
Gentamisin 26±0 13±1 23.33±115 20.33±0.58 nt nt
Co-trimoxazole 30.67±1.15 24.67±1.15 27±1 nt nt nt
Flukonazol nt nt nt nt 24±0 22.33±0.58
a zone of inhibition in mm: <10: weak; >10:moderate; >16: Significant
‒ Lack of activity
nt: not tested
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3. For compounds 1-11 which have different substitution 
pattern on phenyl ring:
a. para-Substitution of the phenyl ring with methoxyl 
4 and methyl 7 increased the activity 64 fold 
corresponding to nonsubstituted phenyl derivative 1. 
Also they showed equipotent activity with standard 
drug gentamicin with 4 µg/ml MIC value.
b. orto- and meta-substitution of the phenyl ring with 
methoxy (compound 2, 3) moiety increased the activity 
4 fold while orto, meta methyl substituted phenyl 
ring increased the activity 2 fold compared to the 
nonsubstituted phenyl derivative 1.
c. MIC values obtained from orto-, meta- and para-
substitution of the phenyl ring with chloro (compound 
8, 9, 10) resulted in a gradually increasing pattern with 
128, 64 and 32 µg/ml respectively.
d. para-Substitution of the phenyl moiety with chloro 
and sulfonamide (compound 10, 11) yielded 8 and 
2 fold more active compounds corresponding to 
nonsubstituted derivative 1 respectively.
Our previous crystallographic study which was accomplished 
with compound 8, 9 and 10 indicated that all these positional 
isomers have different conformational structure and their 
aromaticity changes in the order of 8<10<9 by the means 
of torsion angles and highest occupied molecular orbital 
(HOMA) calculations (30). As their MIC values follow the 
8<9<10 order, conformational changes and electronic effects 
may be considered together as significant parameters for 
antimicrobial activity.
On the other hand, literature survey indicated that 
lipophilicity of the compounds may have an impact on 
antibacterial activity (31). Though, in this study, there wasn’t 
any correlation observed between calculated log P and MIC 
values (Table 2).
Moreover, in one of our study, title compounds 2, 3, 5, 8, 
9, 10 were evaluated for their interaction with DNA and 
suggested to have different binding affinities which are not 
consistent with MIC values (32). Therefore, the antibacterial 
activity may not be suggested as a result of DNA interaction.
Table 2. In vitro anti-bacterial and anti-fungal activities of compounds 1-15 expressed as minimal inhibitory concentration (µg/ml)
Compound No
Bacterial strains Fungal strains
Calc. Log P valuesa
Gram( +) Gram (−)
C.albicans C.parapsilosisS.aureus E.faecalis E.coli P.aeruginosa
1 2048 256 1024 2048 >2048 >2048
2.38
2 1024 64 2048 1024 >2048 >2048
2.39
3 1024 64 2048 2048 >2048 >2048 2.42
4 >2048 4 2048 2048 >2048 >2048
2.44
5 2048 128 >2048 2048 >2048 >2048 2.78
6 2048 128 2048 2048 >2048 >2048 2.81
7 >2048 4 2048 2048 >2048 >2048 2.83
8 1024 128 >2048 >2048 >2048 >2048 3.01
9 1024 64 2048 2048 >2048 >2048 3.04
10 2048 32 2048 2048 >2048 >2048
3.06
11 2048 128 2048 2048 >2048 >2048
1.08
12 2048 256 2048 2048 >2048 >2048
0.31
13 >2048 1024 2048 2048 >2048 >2048
0.78
14 >2048 1024 2048 1024 >2048 >2048 -2.16
15 >2048 2048 2048 2048 >2048 >2048 -3.77
Gentamisin 0.5 4 0.5 0.5 nt nt
Amfoterisin B nt nt nt nt 0.25 0.25
a Calculated by the methodology developed by Molinspiration
nt: not tested
Bold indicating for significant activity
Akgül et al.
Synthesis and Antimicrobial Activity of Some Taurinamide Derivatives Marmara Pharm J 21/2: 361-370, 2017366
In conclusion, the structure activity relationship showed 
that phtalimido moiety, secondary aryl sulphonamide group 
and electron-donating group substitution on phenyl ring are 
essential for selective antibacterial activity. Moreover, para 
substituted methyl and methoxy derivatives of N-phenyl-2-
phthalimidotaurinamide (4, 7), displayed equipotent activity 
compared to standard drug gentamicin against only E. faecalis. 
As most of the serious hospitalized infections caused from 
this bacteria, the title compounds 4 and 7 may be evaluated 
as promising core structures for developing drugs against 
infections caused by E. faecalis type (33, 34).
Experimental
1.General remarks
Aniline, morpholine and sulfanilamide were purchased 
from Merck (Darmstadt, Germany). All other reagents and 
solvents were obtained from Sigma Chemical Co. (St. Louis, 
MO). All solvents used in this study were of analytical grade. 
Compound A and B was prepared as described previously 
(13, 23). 1H NMR spectra were scanned on a Varian AS 
400 Mercury Plus NMR spectrometer using DMSO-d6 as 
solvent. Chemical shifts were reported in parts per million 
(ppm) and the coupling constants (J) were expressed in 
Hertz (Hz). Splitting patterns were designated as follows: s, 
singlet; d, doublet; t, triplet; m, multiplet; brs, broad singlet. 
Infrared spectra were run on a Perkin Elmer Spectrum 100 
FT-IR equipped with a Universal ATR Sampling Accessory 
and the frequencies were expressed in cm-1. Analytical thin-
layer chromatography (TLC) was carried out on Merck silica 
gel F-254 plates. Melting points were taken with an Stuart 
SMP 30 melting point apparatus in open capillary tubes and 
are uncorrected. Elemental analyses (C, H, N and S) were 
performed using a Leco TruSpec CHNS Micro analyzer  (Leco 
Corporation, St. Joseph, MI, USA) and results were within 
±0.4% of calculated values. clog P values were calculated by 
the methodology developed by Molinspiration (35).
2.Chemistry
2.1.Synthesis of 4-(2-phtalimidoethylsulfonamido)
benzenesulfonamide 11.
A solution of 2-phtalimidoethanesulfonyl chloride (1 eqv.) in 
pyridine (5 ml) was treated with p-aminobenzensulfonamide 
(1 eqv.) and heated at 60 ºC until the starting material 
was consumed as evidenced by TLC. The reaction was 
quenched with water and the precipitation was filtered. 
The crude product crystallized from acetic acid:H2O to 
give the 4-(2-(1,3-dioxoisoindolin-2-yl)ethylsulfonamido)
benzenesulfonamide 11 as a white solid.
4-(2-Phtalimidoethylsulfonamido)benzenesulfonamide (11): 
Yield 66%, silica gel TLC Rf 0.56 (EtOAc:Hxn 67% v/v); mp 
244-245 ºC (found), 250-254 ºC (reported) (12). IRʋmax (cm-
1); 1141, 1160 (SO2sym); 1304, 1319 (SO2asym), 1720, 1774 (C=O 
imide); 3264, 3345 (NH2); 3361 (NH). 1H NMR (400 MHz, 
DMSO-d6) δ (ppm): 3.61 (2H, t, J: 7.2 Hz, -CH2CH2SO2NH-), 
4.02 (2H, t, J: 7.2 Hz, -CH2CH2SO2NH-), 7.31 (2H, brs, 
-SO2NH2), 7.34 (2H, d, J: 8.8 Hz, AA’BB’), 7.79 (2H, d, J: 8.8 
Hz, AA’BB’), 7.88 (4H, d, J: 2.4 Hz, phtalimide-H), 10.50 (1H, 
s, -SO2NH-). MS-APCI m/z (intensity%) 410 (1, [M+1]+), 238 
(17), 174 (100). Anal. Calculated for C16H15N3O6S2 (MW = 
409,44): C, 46.94; H, 3.69; N, 10.26; S, 15.66. Found: C, 46.96; 
H, 3.93; N, 10.19; S, 15.77
2.2. Synthesis of 2-(1,3-dioxoisoindolin-2-yl)
ethanesulfonamide 12
Concentrated ammonium hydroxide solution (5 ml) was 
added dropwise to the stirring 2-phtalimidoethanesulfonyl 
chloride (1 eqv.) in an ice bath. The reaction mixture was first 
dissolved and then a white precipitation was formed. After 
observing the consumption of the starting materials by TLC, 
the solvent was evaporated under vacuo, treated with 60% 
acetic acid solution to give a white precipitate which was then 
filtered and crystallized from EtOH:Et2O to furnish the final 
product 2-(1,3-dioxoisoindolin-2-yl)ethanesulfonamide 12 
as a white solid.
2-(1,3-Dioxoisoindolin-2-yl)ethanesulfonamide (12): Yield 
23%, silica gel TLC Rf 0.1 (EtOAc:Hxn 67% v/v); mp 204-
206 ºC (found), 203-205 ºC (reported) (36). IRʋmax (cm-
1); 1136 (SO2sym); 1303 (SO2asym), 1698, 1782 (C=O imide); 
3260, 3356 (NH2). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 
3.37-3.40 (2H, m, -CH2CH2SO2NH2), 3.99-4.02 (2H, m, 
-CH2CH2SO2NH2), 7.06 (2H, brs, -SO2NH2), 7.90 (4H, 
m, phtalimide-H) (36–38). MS-APCI m/z (intensity%) 
255 (1, [M+1]+), 238 (15), 174 (100). Anal. Calculated for 
C10H10N2O4S (MW = 254,26): C, 47.24; H, 3.96; N, 11.02; S, 
12.61 Found: C, 47.27; H, 4.34; N, 11.34; S, 12.62.
2.3 Synthesis of 2-(2-(morpholinosulfonyl)ethyl)
isoindoline-1,3-dione 13.
A solution of 2-phtalimidoethanesulfonyl chloride (1 
eqv.) in DCM (5 ml) was treated with morpholine (1 
eqv.) and TEA (3 eqv.) in an ice bath. The reaction was 
stirred at room temperature until the starting material was 
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consumed as evidenced by TLC. The solvent was evaporated 
under vacuo and treated with water. The white precipitate 
was filtered and crystallized from ethanol to give the 
2-(2-(morpholinosulfonyl)ethyl)isoindoline-1,3-dione 13 as 
white solid.
2-(2-(Morpholinosulfonyl)ethyl)isoindoline-1,3-dione (13): 
Yield 55%, silica gel TLC Rf 0.4 (EtOAc:Hxn 50% v/v); mp 
167-168 ºC. IR
ʋmax (cm-1); 1146 (SO2sym); 1397 (SO2asym), 1719, 
1772 (C=O imide). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 
3.19 (4H, t, J: 4.7 Hz, morpholine-H), 3.50 (2H, t, J: 6.7 Hz, 
-CH2CH2SO2NH-), 3.66 (4H, t, J: 4.7 Hz, morpholine-H), 
4.02 (2H, t, J: 6.7 Hz, -CH2CH2SO2NH-), 7.95-9.88 (4H, 
m, phtalimide-H) (13). MS-APCI m/z (% intensity) 325 
(1, [M+1]+), 238 (67), 174 (100). Anal. Calculated for 
C14H16N2O5S (MW = 324,35): C, 51.84; H, 4.97; N, 8.64; O, 
24.66; S, 9.89. Found: C, 51.57; H, 5.28; N, 8.37; S, 9.84.
2.4. Synthesis of 2-amino-N-phenylethanesulfonamide 
HCl salt 14.
For deprotection of the phtalimido moiety; β-phtalimido-
N-phenylethanesulfonamide (1 eqv.) was suspended in 4 ml 
ethanol and treated with 80% hydrazine hydrate (0.87 eqv.) 
solution according to ing-manske procedure. The reaction 
mixture was refluxed for three hours and evaporated under 
vacuo. The crude product dissolved in water and acidified 
with 1 eqv. conc. HCl solution. The precipitate was filtered, 
evaporated under vacuo and crystallized from isopropanol 
to give 2-amino-N-phenylethanesulfonamide HCl salt 14 as 
white solid.
2-Amino-N-phenylethanesulfonamide HCl salt (14): Yield 
37%, silica gel TLC Rf 0.27 (MeOH/DCM 17% v/v); mp 173-
175 ºC (found), 178-180 ºC (reported) (39). IRʋmax (cm-1); 
1141 (SO2sym); 1321 (SO2asym); 2624 (NH3+); 3357 (NH). 1H 
NMR (400 MHz, DMSO-d6) δ (ppm): 3.14 (2H, t, J: 8.0 Hz, 
-CH2CH2SO2NH2), 3.47 (2H, t, J: 7.5 Hz, -CH2CH2SO2NH2), 
7.18 (1H, t, J: 8.0 Hz, Ar-H), 7.30 (2H, t, J: 8.0 Hz, 2×Ar-
H), 7.39 (2H, t, J: 8.0 Hz, 2×Ar-H) (39). MS-APCI m/z 
(intensity%) 201 (16, [M+1]+), 94 (100). Anal. Calculated for 
C8H13ClN2O2S (0.6 H2O) (0.3 HCl) (MW = 236,72): C, 37.18; 
H, 5.65; Cl, 17.83; N, 10.84; S, 12.41. Found: C, 37.02; H, 5.57; 
N, 11.18; S, 12.08.
2.5. Synthesis of 2-(morpholinosulfonyl)ethanamine HCl 
salt 15
2-(2-(Morpholinosulfonyl)ethyl)isoindoline-1,3-dione (1 
eqv.) was refluxed with 4 ml ethanol and 80% hydrazine 
hydrate (0.87 eqv.) solution until the consumption of the 
starting materials (observed with TLC) and evaporated 
under vacuo. The crude product dissolved in water and 
phtalhydrazide precipitated after adding 1 eqv. conc. HCl 
solution. The mixture was filtered, evaporated under vacuo. 
The solid was triturated with ethyl acetate: n-hexane and 
crystallized from isopropanol to give the target compound 
2-(morpholinosulfonyl)ethanamine HCl salt 15 as white solid.
2-(Morpholinosulfonyl)ethanamine HCl salt (15): Yield 
63%, silica gel TLC Rf 0.67 (EtOAc:Hxn 80% v/v); mp 162-
163 ºC. IRʋmax (cm-1): 1108 (SO2sym); 1329 (SO2asym); 2857 
(NH3+). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 3.18 (2H, 
brs, -CH2CH2SO2NH-), 3.23 (4H, t, J: 4.8 Hz, morpholine-H), 
3.56 (2H, t, J: 7.5 Hz, -CH2CH2SO2NH-), 3.69 (4H, t, J: 4.8 
Hz, morpholine-H), 8.44 (3H, s, NH3+) (13). MS-APCI m/z 
(intensity%): 195 (100, [M+1]+), 88 (81). Anal. Calculated for 
C6H15ClN2O3S (0.1 H2O) (MW = 230,71): C, 30.99; H, 6.59; 
N, 12.05; S, 13.79. Found: C, 30.80; H, 6.84; N, 12.16; S, 13.62.
3. Antimicrobial activity
In vitro antimicrobial activities of the compounds 1-15 were 
evaluated by disc diffusion and broth microdilution methods 
against various bacterial and fungal strains.
3.1. Microorganisms
The following bacterial and fungal strains were used: 
Staphylococcus aureus (ATCC 25923), Staphylococcus aureus 
(ATCC 29213), Enterococcus faecalis (ATCC 29212), Escherichia 
coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), 
Candida albicans (ATCC 90028) and Candida parapsilosis 
(ATCC 22019). All strains were stored in Brain-Heart Infusion 
Broth (Merck, Germany) with 10% glycerol at -80 °C. Müller-
Hinton agar (MHA) and Sabouraud dextrose agar (SDA) 
(Oxoid, UK) were used for bacteria and yeasts, respectively.
3.2. Disc diffusion test
Inhibition zone diameters of the strains were assesed 
by Clinical and Laboratory Standards Institute (CLSI) 
recommendations with minor modifications (40, 41). The 
compounds were prepared solving in dimethyl sulfoxide 
(DMSO). Sterile empty discs (6 mm diameter) (Oxoid, 
UK) impregnated with 10 μl of each formulation (10 mg/
ml DMSO) were placed on the inoculated MHA and SDA 
plates and the plates were incubated at 37 °C 24 h for bacteria 
and 48 h for yeasts. All solutions were sterilized with 0.22 
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µm pore size filters. Gentamisin (Oxoid, Germany) and 
trimethoprim/sulfamethoxazole (co-trimoxazole) (Oxoid, 
Germany) discs were used as reference for bacteria and 
fluconazole (1 mg/ml) (Sigma-Aldrich, Germany) were used 
as reference for yeasts. DMSO was also tested separately and 
each sample was tested in triplicate. After incubation periods 
of 16-20 hours for bacteria and 48 hours for yeasts, the 
diameters of the growth inhibition zones were measured and 
means ± standard deviations (SD) were reported.
3.3. Determination of minimum inhibitory concentration 
(MIC)
The minimum inhibitory concentrations of the compounds 
were evaluated for each strain using the broth microdilution 
method as described by Kotmakçı et al. (42) with minor 
modification. Mueller-Hinton II broth (cation adjusted) 
(MHIIB) (Merck, Germany) and Sabouraud dextrose broth 
(SDB) (Oxoid, UK) were used for broth microdilution for 
bacteria and yeasts, respectively. The experiments were 
performed in 96-well microtitration plates using 50 µl inoculum 
of all strains with ½ serial dilutions of the compounds. The 
final concentrations of the compounds were ranged from 
2048 to 1 µg/ml. The lowest concentrations that have no 
visible microbial growth is determined as MIC. Gentamicin 
(İ.E. Ulugay, Turkey) and fluconazole were used as reference 
agents for antibacterial and antifungal activities, respectively. 
Quality control ranges were evaluated according to CLSI (40). 
Each sample was tested in triplicate and DMSO was also tested 
separately for antibacterial and antifungal activity.
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